Pharmaceutical company specializing on identifying and developing clinical stage compounds for orphan diseases and other diseases with high unmet medical needs Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB:TRYPF) announced having entered into partnership with University of Michigan to carry out research related to Tryp’s psilocybin for neuropsychiatric disorders program.
This partnership comes as part of a string of upcoming bridging studies designs to expand Tryp’s intellectual portfolio for its novel TRP-8803 drug formulation compared with conventional oral formulations of synthetic psilocybin.
The string of studies will also facilitate the advancement of TRP-8803 into Phase 2b clinical trials.
“We are excited to initiate our collaboration with the University of Michigan with critical research supporting the unique properties of our proprietary psilocybin formulation and method of delivery. The University of Michigan has extensive expertise in the dosing and delivery of active pharmaceutical ingredients and world-class expertise in several pain related indications that are aligned with our interests. We expect this to be the first of many opportunities for collaboration with this prestigious academic institution,” said President and Chief Science Officer of Tryp, Jim Gilligan.
